IDIBELL and ICFO Researchers Develop Technology that Predicts Metastasis in Breast Cancer
Monday, October 22, 2012
Raman is a promising microspectroscopy technique for identifying metastatic phenotype of breast cancer cells from their lipid profile.
SDSC to House Data Repository for NIH Metabolomics Project
Thursday, October 18, 2012
UC San Diego bioengineers to play key role in the five-year, $6 million program.
COSMOS to Set Standards in Metabolomics
Thursday, October 18, 2012
Project launch is a global effort to enable free and open sharing of metabolomics data.
Biochemists Open Path for Possible Molecular ‘Chaperone’ Therapy
Tuesday, October 16, 2012
UMass scientists identify molecule that could help treat metabolic disorder.
Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism
Monday, October 15, 2012
Metabolon’s partners will collaborate toward shared objectives through this program.
Tissue of Origin Determines Cancer-associated CpG Island Promoter Hypermethylation Patterns
Friday, October 05, 2012
Meehan, Sproul and co-workers conclude that general aberrant promoter hypermethylation in cancer does not promote tumorigenesis, but instead reinforces transcription repression inherited from pre-cancerous tissue.
Non-Genotoxic Carcinogen Exposure Induces Defined Changes in the 5-Hydroxymethylome
Friday, October 05, 2012
In a genome wide study Meehan, Moggs and MARCAR co-authors examined 5mC and 5hmC profiles of liver in control and phenobarbital treated mice. They observe dynamic and reciprocal changes in the 5mC/5hmC patterns over genes promoters that are transcriptionally up-regulated.
Novel Biomarkers for Pre-Diabetes Identified by Metabolomics
Friday, October 05, 2012
Researchers have demonstrated that targeting the pathways that involve new potential biomarkers would help to take preventive steps against type 2 diabetes at an earlier stage.
LECO and Genedata Collaborate on Mass Spectrometry Data Analysis
Thursday, September 27, 2012
Efficient mass spectrometry data analysis capabilities now available to a broad range of pharmaceutical, industrial biotech, and life science companies.
|
|
|
|
|
|
